Form 4: Nurix Therapeutics CFO Hans van Houte Sells Shares Under 10b5-1 Trading Plan

Hans van Houte, CFO of Nurix Therapeutics, sold 3,499 shares of common stock at an average price of $12.826 per share on May 2, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On May 2, 2024, Hans van Houte, the Chief Financial Officer of Nurix Therapeutics, sold 3,499 shares of the company's common stock.
• The sale was executed at a weighted average price of $12.826 per share.
• The price range for the shares sold was between $12.65 and $13.10.
• The transaction was conducted under a pre-existing Rule 10b5-1 trading plan.
• Following the transaction, van Houte directly owns 68,333 shares of Nurix Therapeutics.
• The reporting person has undertaken to provide full information regarding the total number of shares sold at each separate price within the range set forth.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale under a pre-arranged trading plan. It doesn't inherently indicate positive or negative prospects for the company.

Industry Context

Sales by company insiders are a common occurrence and are often pre-planned through Rule 10b5-1 trading plans to avoid accusations of insider trading. The market typically views these sales in the context of the individual's overall holdings and the reasons behind the sale, which are not always disclosed.

Stakeholder Impact

• The sale of shares by a company executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates